Novo Nordisk and Pfizer have escalated their competing bids for obesity drug developer Metsera to approximately $10 billion, transforming what began as a straightforward acquisition into a high-stakes corporate battle marked by legal challenges and regulatory scrutiny. Metsera’s board declared
Eli Lilly and Company has announced plans to construct a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. The facility will expand Lilly’s global capacity to produce oral medicines and strengthen its
Eli Lilly and Company has announced plans to invest more than $1.2 billion to expand and modernise its Lilly del Caribe manufacturing site in Carolina, Puerto Rico. The investment will integrate advanced technologies and expand production capacity to support the
Lupin Limited, a global pharmaceutical company, has inaugurated its new corporate offices at 100 Somerset Corporate Blvd in Bridgewater, New Jersey. The move strengthens Lupin’s presence in the state, where it already operates manufacturing and research facilities in Somerset. The
Takeda Pharmaceutical Company has entered a global strategic partnership with China’s Innovent Biologics to acquire rights to two late-stage investigational oncology medicines and an option on an early-stage program, the companies announced October 22. Under the agreement, Takeda will pay
Merck, known as MSD outside the United States and Canada, has broken ground on a $3 billion pharmaceutical manufacturing facility at its Elkton, Virginia site. The 400,000-square-foot Center of Excellence for Pharmaceutical Manufacturing will expand the company’s small molecule manufacturing
AstraZeneca has announced a $4.5 billion investment in a new manufacturing facility at Rivanna Futures, Albemarle County, Virginia. The funding, a $500 million increase on initial plans, will expand the facility’s capability to manufacture a broader range of medicines, including
Lupin has announced plans to build a new state-of-the-art pharmaceutical manufacturing plant in Coral Springs, Florida, with a projected cumulative investment of $250 million over five years. The facility will produce more than 25 critical respiratory medicines, including albuterol inhalers
Cytiva’s third Global Biopharma Index reports a decline in overall industry resilience amid ongoing talent shortages and increasing regulatory pressures. Every two years, Cytiva surveys 1,250 biopharma executives across 22 countries, asking them to rate the industry ecosystem on a
Eli Lilly and Company announced plans to invest more than $1 billion over the next several years in contract manufacturing partnerships across India, marking a significant expansion of the company’s global manufacturing footprint and its commitment to the country’s pharmaceutical
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
